Bertrand Tombal, MD, PhD, Catholic University of Leuven, Leuven, Belgium, discusses the ARASENS trial for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the three pillars of prostate cancer treatment: androgen deprivation therapy, androgen receptor suppression, and chemotherapy. Prof. Tombal introduces the hypothesis that combining these treatments will improve overall survival (OS), on which the Phase III ARASENS trial (NCT02799602) is based, and outlines the design of this study.
ARASENS: Will combining different treatments improve prostate cancer survival?
